Medtronic PLC (NYSE:MDT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Medtronic PLC (NYSE:MDT) have earned an average rating of “Moderate Buy” from the twenty-three analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $102.8235.

MDT has been the subject of several analyst reports. Daiwa Capital Markets boosted their price objective on Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a report on Friday, September 12th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. Sanford C. Bernstein upped their price target on Medtronic from $97.00 to $98.00 and gave the stock an “outperform” rating in a report on Wednesday, August 20th. William Blair raised Medtronic to a “hold” rating in a report on Friday, July 11th. Finally, Citigroup upped their price target on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th.

Insider Transactions at Medtronic

In other news, Director William R. Jellison acquired 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.26% of the company’s stock.

Institutional Investors Weigh In On Medtronic

Several large investors have recently bought and sold shares of MDT. Brighton Jones LLC increased its stake in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. GAMMA Investing LLC increased its stake in Medtronic by 41.1% during the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock worth $1,427,000 after buying an additional 4,626 shares in the last quarter. Golden State Wealth Management LLC increased its stake in Medtronic by 180.8% during the 1st quarter. Golden State Wealth Management LLC now owns 2,752 shares of the medical technology company’s stock worth $247,000 after buying an additional 1,772 shares in the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Medtronic by 7.5% in the first quarter. Perigon Wealth Management LLC now owns 13,735 shares of the medical technology company’s stock valued at $1,234,000 after purchasing an additional 953 shares during the last quarter. Finally, Western Wealth Management LLC increased its holdings in shares of Medtronic by 14.9% in the first quarter. Western Wealth Management LLC now owns 5,628 shares of the medical technology company’s stock valued at $506,000 after purchasing an additional 730 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of MDT stock opened at $93.76 on Friday. The stock has a market cap of $120.26 billion, a PE ratio of 25.83, a price-to-earnings-growth ratio of 2.48 and a beta of 0.78. The business has a 50-day simple moving average of $94.32 and a 200-day simple moving average of $89.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic has a 52-week low of $79.29 and a 52-week high of $99.37.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities analysts expect that Medtronic will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.